|
Market Closed -
Nasdaq Copenhagen
08:50:00 17/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 39.45 DKK | +0.25% |
|
-9.62% | +8.98% |
| 11/09 | Lundbeck's Asedebart Gets US FDA Orphan Drug Designation for Endogenous Cushing's Syndrome | MT |
| 11/09 | Lundbeck wins US orphan drug status for asedebart in Cushing's syndrome | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Pharmaceuticals Wholesale
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 10TCr | |||||
| 5.41TCr | |||||
| 2.12TCr | |||||
| 799.24Cr | |||||
| 686.59Cr |
- Stock Market
- Stocks
- HLUN B Stock
- LUN Stock
- Charts Lundbeck
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
